Cure Parkinson's approves funding for new iron removing drug
Cure Parkinson’s continues to champion iron chelation for Parkinson's. Trustees have now awarded a grant to develop the next generation of iron reducing drugs.
Learn more
Iron and the brain
Recent studies exploring iron levels in the brains of people with Parkinson’s have shown important implications for its use as a biomarker, as well as a way of potentially assessing the progression of the condition.
ACT PD – the next generation of clinical trials for Parkinson’s
Would you be interested in joining the ACT PD project team? Funded by the Edmond J. Safra foundation, this 3-year programme will bring together national and international experts to develop a protocol and sustainable strategy for a multi-arm, multi-stage trial platform to investigate disease modifying…
The Multiple Sclerosis MAMS model for Parkinson’s
One of the most frustrating aspects of the way we currently conduct clinical trials is the long delays between studies. Multi-Arm, Multi-Stage (or MAMS) clinical trials may represent a solution to this cumbersome problem.
iLCT provides template for drug repurposing in other conditions
The International Linked Clinical Trials programme (iLCT) is one of the largest drug repurposing initiatives in medical research. A recent review article provides an overview of the history, structure and progress of this successful programme.
Van Andel Institute: Virtual public lecture series
Van Andel Institute are holding a virtual webinar as part of their “Public Lecture Series”. This informative event will feature presentations and a Q&A session with international Parkinson’s disease experts including Cure Parkinson’s Director of Research, Dr Richard Wyse and Deputy Director of Research, Dr Simon…